Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome + 5-FU/LV + Bevacizumab in First-line mCRC
NCT06341296Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in metastatic colorectal cancer (mCRC), sponsored by West China Hospital of Sichuan University. Started Jun 2024; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06341296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341296.